TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice

Journal of Clinical Investigation

Volumn 124, Issue 12, 2014, Pages 5225-5238

  Rahaman, Shaik O ^a   Grove, Lisa M ^a   Paruchuri, Sailaja ^a   Southern, Brian D ^a   Abraham, Susamma ^a   Niese, Kathryn A ^a   Scheraga, Rachel G ^a   Ghosh, Sudakshina ^a   Thodeti, Charles K ^b   Zhang, David X ^c   Moran, Magdalene M ^d   Schilling, William P ^e   Tschumperlin, Daniel J ^f   Olman, Mitchell A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Northeastern Ohio Medical University   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d Hydra Biosciences Inc   (United States)

^e METROHEALTH MEDICAL CENTER   (United States)

^f MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CALCIMYCIN; CALCIUM ION; F ACTIN; G ACTIN; MYOSIN ADENOSINE TRIPHOSPHATASE; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; VANILLOID RECEPTOR 4; ANTINEOPLASTIC ANTIBIOTIC; MKL1 PROTEIN, MOUSE; TGFB1 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN; TRPV4 PROTEIN, MOUSE; VANILLOID RECEPTOR;

ACTIN POLYMERIZATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL MEMBRANE; CONTROLLED STUDY; EXPERIMENTAL PULMONARY FIBROSIS; EXTRACELLULAR CALCIUM; FEMALE; FIBROGENESIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LOW DRUG DOSE; LUNG COMPLIANCE; LUNG FIBROBLAST; LUNG PARENCHYMA; MOUSE; MYOFIBROBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RIGIDITY; UPREGULATION; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; EXTRACELLULAR MATRIX; GENETICS; LUNG; LUNG FIBROSIS; METABOLISM; MUTANT MOUSE STRAIN; PATHOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CELL DIFFERENTIATION; EXTRACELLULAR MATRIX; FEMALE; LUNG; MICE; MICE, MUTANT STRAINS; MYOFIBROBLASTS; PULMONARY FIBROSIS; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA1; TRPV CATION CHANNELS; UP-REGULATION;

EID: 84915748921     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI75331     Document Type: Article

References (59)

1. Raghu G, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
2. Noth I, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186(1):88-95.
3. Richeldi L, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079-1087.
4. Idiopathic Pulmonary Fibrosis Clinical Research Network, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968-1977.
5. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949-1961.
6. Chapman HA. Disorders of lung matrix remodeling. J Clin Invest. 2004;113(2):148-157.
7. Hinz B, et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012;180(4):1340-1355.
8. Muro AF, et al. An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177(6):638-645.
9. Marinkovic A, Mih JD, Park JA, Liu F, Tschumperlin DJ. Improved throughput traction microscopy reveals pivotal role for matrix stiffness in fibroblast contractility and TGF-β responsiveness. Am J Physiol Lung Cell Mol Physiol. 2012;303(3):L169-L180.
10. Grinnell F, Ho CH. Transforming growth factor beta stimulates fibroblast-collagen matrix contraction by different mechanisms in mechanically loaded and unloaded matrices. Exp Cell Res. 2002;273(2):248-255.
11. Liu F, et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol. 2010;190(4):693-706.
12. Zhou Y, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest. 2013;123(3):1096-1108.
13. Wells RG. Tissue mechanics and fibrosis. Biochim Biophys Acta. 2013;1832(7):884-890.
14. Shimbori C, Gauldie J, Kolb M. Extracellular matrix microenvironment contributes actively to pulmonary fibrosis. Curr Opin Pulm Med. 2013;19(5):446-452.
15. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4(7):517-529.
16. Ramires FJ, Sun Y, Weber KT. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. J Mol Cell Cardiol. 1998;30(3):475-483.
17. 2+ signals confer fibrogenesis in human atrial fibrillation. Circ Res. 2010;106(5):992-1003.
18. Davis J, Burr AR, Davis GF, Birnbaumer L, Molkentin JD. A TRPC6-dependent pathway for myofibroblast transdifferentiation and wound healing in vivo. Dev Cell. 2012;23(4):705-715.
19. Biernacka A, Dobaczewski M, Frangogiannis NG. TGFβ signaling in fibrosis. Growth Factors. 2011;29(5):196-202.
20. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028-1040.
21. Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 2012;11(10):790-811.
22. Zhu MX, ed. TRP Channels. Boca Raton, Florida, USA: CRC Press; 2011.
23. Venkatachalam K, Montell C. TRP channels. Annu Rev Biochem. 2007;76:387-417.
24. Liedtke W. Molecular mechanisms of TRPV4-mediated neural signaling. Ann N Y Acad Sci. 2008;1144:42-52.
25. Vriens J, Watanabe H, Janssens A, Droogmans G, Voets T, Nilius B. Cell swelling, heat, and chemical agonists use distinct pathways for the activation of the cation channel TRPV4. Proc Natl Acad Sci U S A. 2003;101(1):396-401.
26. Lamandé SR, et al. Mutations in TRPV4 cause an inherited arthropathy of hands and feet. Nat Genet. 2011;43(11):1142-1146.
27. Auer-Grumbach M, et al. Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat Genet. 2010;42(2):160-164.
28. Deng HX, et al. Scapuloperoneal spinal muscular atrophy and CMT2C are allelic disorders caused by alterations in TRPV4. Nat Genet. 2009;42(2):165-169.
29. Masuyama R, et al. TRPV4-mediated calcium influx regulates terminal differentiation of osteoclasts. Cell Metab. 2008;8(3):257-265.
30. Muramatsu S, et al. Functional gene screening system identified TRPV4 as a regulator of chondrogenic differentiation. J Biol Chem. 2007;282(44):32158-32167.
31. Adapala RK, et al. TRPV4 channels mediate cardiac fibroblast differentiation by integrating mechanical and soluble signals. J Mol Cell Cardiol. 2013;54:45-52.
32. Hamanaka K, et al. TRPV4 initiates the acute calcium-dependent permeability increase during ventilator-induced lung injury in isolated mouse lungs. Am J Physiol Lung Cell Mol Physiol. 2007;293(4):L923-L932.
33. Thorneloe KS, et al. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. Sci Transl Med. 2012;4(159):159ra148.
34. Thorneloe KS, et al. N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxy-propanoyl)-1-piperazinyl]carbonyl}-meth-ylbutyl)-1-benzothiophene-2 carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I. J Pharmacol Exp Ther. 2008;326(2):432-442.
35. Vincent F, et al. Identification and characterization of novel TRPV4 modulators. Biochem Biophys Res Commun. 2009;389(3):490-494.
36. 2+ waves and enhances gene expression in human pulmonary fibroblasts. Am J Respir Cell Mol Biol. 2012;46(6):757-764.
37. Everaerts W, et al. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci U S A. 2010;107(44):19084-19089.
38. Zhu S, et al. Urokinase receptor mediates lung fibroblast attachment and migration toward provisional matrix proteins through interaction with multiple integrins. Am J Physiol Lung Cell Mol Physiol. 2009;297(1):L97-L108.
39. Sandbo N, Lau A, Kach J, Ngam C, Yau D, Dulin NO. Delayed stress formation mediates pulmonary myofibroblast differentiation in response to TGF-β. Am J Physiol Lung Cell Mol Physiol. 2011;301(5):L656-L666.
40. Sandbo N, Dulin NO. Actin cytoskeleton in myofibroblast differentiation: ultrastructure defining form and driving function. Transl Res. 2011;158(4):181-196.
41. Cen B, et al. Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes. Mol Cell Biol. 2003;3(18):6597-6608.
42. Zhu G, et al. Association of TRPV4 gene polymorphisms with chronic obstructive pulmonary disease. Hum Mol Genet. 2009;18(11):2053-2062.
43. Follonier Castella L, Gabbiani G, McCulloch CA, Hinz B. Regulation of myofibroblast activities: calcium pulls some strings behind the scene. Exp Cell Res. 2010;316(15):2390-2401.
44. Schwartz MA. Integrins and extracellular matrix in mechanotransduction. Cold Spring Harb Perspect Biol. 2010;2(12):a005066.
45. Thodeti CK, et al. TRPV4 channels mediate cyclic strain-induced endothelial cell reorientation through integrin-to-integrin signaling. Circ Res. 2009;104(9):1123-1130.
46. Matthews BD, Thodeti CK, Tytell JD, Mammoto A, Overby DR, Ingber DE. Ultra-rapid activation of TRPV4 ion channels by mechanical forces applied to cell surface beta1 integrins. Integr Biol (Camb). 2010;2(9):435-442.
47. Mih JD, Sharif AS, Liu F, Marinkovic A, Symer MM, Tschumperlin DJ. A multiwell platform for studying stiffness-dependent cell biology. PLoS One. 2011;6(5):e19929.
48. Barkauskas CE, Noble PW. Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis. Am J Physiol Cell Physiol. 2014;306(11):C987-C996.
49. Hutchison N, Fligny C, Duffield JS. Resident mesenchymal cells and fibrosis. Biochim Biophys Acta. 2013;1832(7):962-971.
50. Tanjore H, et al. Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med. 2009;180(7):657-665.
51. Hung C, et al. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med. 2013;188(7):820-830.
52. Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol. 2011;179(3):1074-1080.
53. Hashimoto N, Jin H, Liu T, Chensue SW, Phan SH. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest. 2004;113(2):243-252.
54. Moran MM, McAlexander MA, Bíró T, Szallasi A. Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov. 2011;10(8):601-620.
55. Mizuno A, Matsumoto N, Imai M, Suzuki M. Impaired osmotic sensation in mice lacking TRPV4. Am J Physiol Cell Physiol. 2003;285(1):C96-C101.
56. 2+ entry. J Am Heart Assoc. 2013;2(3):e000080.
57. Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest. 1995;96(3):1621-1630.
58. Ding Q, et al. FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis. Am J Pathol. 2013;182(5):1572-1584.
59. Grove LM, et al. Urokinase-type plasminogen activator receptor (uPAR) ligation induces a raft-localized integrin signaling switch that mediates the hypermotile phenotype of fibrotic fibroblasts. J Biol Chem. 2014;289(18):12791-12804.